Veracyte, Inc.
VCYT
$32.13
$1.203.88%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.01% | 16.41% | 19.91% | 23.42% | 23.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.01% | 16.41% | 19.91% | 23.42% | 23.46% |
| Cost of Revenue | 5.61% | 21.77% | 20.71% | 21.22% | 26.03% |
| Gross Profit | 20.89% | 14.19% | 19.56% | 24.42% | 22.30% |
| SG&A Expenses | 7.67% | 0.78% | 4.90% | 5.45% | 5.09% |
| Depreciation & Amortization | -11.42% | -15.00% | -19.85% | -23.77% | -27.81% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.42% | 6.50% | 9.49% | 10.70% | 11.94% |
| Operating Income | 223.34% | 409.29% | 3,972.03% | 372.39% | 221.68% |
| Income Before Tax | 164.92% | 479.51% | 152.87% | 149.81% | 133.60% |
| Income Tax Expenses | 15.07% | -36.83% | 451.20% | 190.19% | 172.74% |
| Earnings from Continuing Operations | 174.89% | 427.11% | 148.73% | 148.48% | 132.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 174.89% | 427.11% | 148.73% | 148.48% | 132.44% |
| EBIT | 223.34% | 409.29% | 3,972.03% | 372.39% | 221.68% |
| EBITDA | 102.73% | 122.56% | 152.63% | 319.05% | 381.49% |
| EPS Basic | 168.82% | 375.89% | 145.78% | 145.78% | 130.60% |
| Normalized Basic EPS | 152.39% | 151.16% | 311.22% | 1,548.62% | 437.55% |
| EPS Diluted | 174.97% | 349.37% | 143.73% | 143.67% | 128.80% |
| Normalized Diluted EPS | 153.44% | 151.74% | 307.01% | 1,519.76% | 431.16% |
| Average Basic Shares Outstanding | 2.75% | 3.76% | 4.65% | 5.47% | 5.28% |
| Average Diluted Shares Outstanding | 2.98% | 4.79% | 6.37% | 7.65% | 6.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |